2019 年第 12 期 第 14 卷

利伐沙班用于非瓣膜性心房颤动抗凝治疗的研究进展

Research progress of rivaroxaban in anticoagulant therapy for non-valvular atrial fibrillation

作者：刘雪李学文

英文作者：

单位：030031太原，山西医科大学附属大医院山西大医院心血管内科

英文单位：

关键词：非瓣膜性心房颤动；利伐沙班；抗凝治疗

英文关键词：

• 摘要：

• 【摘要】非瓣膜性心房颤动的患病率及其导致的血栓栓塞风险均随年龄增长而逐渐升高，而我国人口老龄化程度持续加深，心房颤动导致的卒中具有高致残率、高复发率及高病死率的特点，而合理的抗凝治疗可显著降低心房颤动患者卒中的发生率，因此抗凝成为心房颤动患者治疗的重中之重。华法林作为我国一线抗凝药物，由于需要频繁监测国际标准化比值且易与食物、药物相互作用等不足极大地降低了患者的服药依从性，新型口服抗凝药利伐沙班的问世给心房颤动患者带来了新的福祉。本文对利伐沙班的药理及药代动力学、给药方案、出血处理、监测指标和在特殊人群中的应用等方面进行综述。

• 【Abstract】The prevalence of non-valvular atrial fibrillation and the risk of thromboembolism increase with age. China is entering an aging society. Stroke induced by atrial fibrillation has high rates of disability, recurrence and mortality. Reasonable anticoagulant therapy can significantly reduce the incidence of stroke in patients with atrial fibrillation and anticoagulation is the most important treatment. Warfarin, a first-line anticoagulant agent in China, needs frequent monitoring of international normalized ratio and is easy to interact with food and drugs, which greatly reduce the compliance of patients. Rivaroxaban is a new oral anticoagulant drug that brings benefits for the treatment of atrial fibrillation. This article introduced the pharmacological and pharmacokinetic characteristics, dosing regimen, countermeasures of bleeding event, monitoring indicators and the application of rivaroxaban in atrial fibrillation patients.